Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,466JPY
17 Jan 2017
Change (% chg)

¥-11 (-0.44%)
Prev Close
¥2,478
Open
¥2,500
Day's High
¥2,501
Day's Low
¥2,466
Volume
1,583,100
Avg. Vol
2,607,517
52-wk High
¥2,750
52-wk Low
¥2,078

Select another date:

Mon, Jan 9 2017

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan

Kite Pharma partners with Japan's Daiichi for cancer therapy

Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

Kite Pharma partners with Japan's Daiichi for cancer therapy

Jan 9 Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration

* Pieris Pharmaceuticals to receive GLP tox milestone payment in Daiichi Sankyo collaboration

BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond

* Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology

BRIEF-Daiichi Sankyo completes 20.2 mln shares' buy-back for 50 bln yen

* Says it completes around 20.2 million shares' buy-back for approximately 50 billion yen as of Oct. 24

BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration

* Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

Daiichi Europe execs need not testify in Benicar MDL - judge

By Brendan Pierson Japanese drugmaker Daiichi Sankyo Co Ltd does not have to produce two managers from its European affiliate for deposition in a multidistrict litigation claiming its blood pressure drug Benicar causes severe gastrointestinal problems, a federal magistrate judge has ruled.

Select another date: